XML 71 R53.htm IDEA: XBRL DOCUMENT v3.22.4
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurement by Fair Value Hierarchy Level During the periods
presented, there were no transfers between fair value hierarchical levels.
Fair Value Measurements At Reporting Date
Description
Balance at December 31,
2022
Quoted prices
in active
markets
Level 1
Significant
other observable
inputs
Level 2
Significant
unobservable
inputs
Level 3
Measured at
Net Asset Value
as a Practical
Expedient (2)
(amounts in thousands)
Assets
Interest rate cash flow hedge (3)
$4,012 $— $4,012 $— $— 
Liabilities
Deferred compensation plan liabilities (1)
$24,123 $19,944 $— $— $4,179 
Contingent Consideration (4)
$12 $— $— $12 $— 
Description
Balance at December 31,
2021
Quoted prices
in active
markets
Level 1
Significant
other observable
inputs
Level 2
Significant
unobservable
inputs
Level 3
Measured at
Net Asset Value
as a Practical
Expedient (2)
(amounts in thousands)
Liabilities
Deferred compensation plan liabilities (1)
$32,730 $26,839 $— $— $5,891 
Interest rate cash flow hedge (3)
$394 $— $394 $— $— 
Contingent Consideration (4)
$8,783 $— $— $8,783 $— 
(1)The Company’s deferred compensation liability, which is included in other long-term liabilities, is recorded at fair value on a recurring basis. The unfunded plan allows participants to hypothetically invest in various specified investment options.
(2)The fair value of underlying investments in collective trust funds is determined using the net asset value (“NAV”) provided by the administrator of the fund as a practical expedient. The NAV is determined by each fund’s trustee based upon the fair value of the underlying assets owned by the fund, less liabilities, divided by outstanding units. In accordance with appropriate accounting guidance, these investments have not been classified in the fair value hierarchy.
(3)The Company’s interest rate collar, which is included in other long-term liabilities at December 31, 2021 and other assets, net of accumulated amortization at December 31, 2022, is recorded at fair value on a recurring basis. The derivatives are not exchange listed and therefore the fair value is estimated using models that reflect the contractual terms of the derivative, yield curves, and the credit quality of the counterparties. The models also incorporate the Company’s creditworthiness in order to appropriately reflect non-performance risk. Inputs are generally observable and do not contain a high level of subjectivity.
(4)In connection with the Podcorn Acquisition, the Company recorded a liability for contingent consideration payable based upon the achievement of certain annual performance benchmarks over 2 years. The fair value of the liability is estimated using probability-weighted, discounted future cash flows at current tax rates using a scenario based model, and remeasured quarterly. The significant unobservable inputs (Level 3) used to estimate the fair value included the projected Adjusted EBITDA values for 2022 and 2023, as defined in the purchase agreement, and the discount rate. Using an initial discount rate of 10.5%, the fair value of the contingent consideration was $7.7 million at the acquisition date. Due to fluctuation in the market-based inputs used to develop the discount rate, the discount rate decreased to 9.0% at December 31, 2022. Additionally, a reduction in Adjusted EBITDA values for 2022 resulted in a lower expected present value of the contingent consideration. As a result, the fair value of the contingent consideration at December 31, 2022 decreased $8.8 million to $0.1 million. This balance is included in other long-term liabilities.
Schedule of Carrying Value of Financial Instruments
The following table presents the carrying value of financial instruments and, where practicable, the fair value as of the periods indicated:
December 31,
2022		December 31,
2021
Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
(amounts in thousands)
Term B Loans (1)
$632,415 $454,548 $632,415 $626,881 
Revolver (2)
$180,000 $180,000 $97,727 $97,727 
2029 Notes (3)
$540,000 $92,138 $540,000 $527,850 
2027 Notes (3)
$460,000 $82,513 $470,000 $460,600 
Accounts receivable facility (4)
$75,000 $75,000 
Other debt (4)
$752 $764 
Letters of credit (4)
$6,069 $6,069 
The following methods and assumptions were used to estimate the fair value of financial instruments:
(1)The Company’s determination of the fair value of the Term B-2 Loan was based on quoted prices for these instruments and is considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(2)The fair value of the Revolver was considered to approximate the carrying value as the interest payments are based on LIBOR rates that reset periodically. The Revolver is considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(3)The Company utilizes a Level 2 valuation input based upon the market trading prices of the 2029 Notes and 2027 Notes to compute the fair value as these 2029 Notes and 2027 Notes are traded in the debt securities market. The 2029 Notes and 2027 Notes are considered a Level 2 measurement as the pricing inputs are other than quoted prices in active markets.
(4)The Company does not believe it is practicable to estimate the fair value of the accounts receivable facility, other debt or the outstanding standby letters of credit.
Schedule of Cost Method Investments The following table presents the Company’s investments valued under the measurement alternative: 
Investments Valued Under the
Measurement Alternative
December 31,
20222021
(amounts in thousands)
Investment balance before cumulative impairment as of January 1,$3,005 $3,305 
Accumulated impairment as of January 1,— — 
Investment beginning balance after cumulative impairment as of January 1,3,005 3,305 
Disposal of investment in a privately held company(300)
Ending period balance$3,005 $3,005